U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for “Difficult-to-Treat” HCV Genotype 1 Patients

By Ho Samuel   Aqel Bashar   Dieperink Eric   Liu Shanglei   Tetrick Lori   Falck-Ytter Yngve   DeComarmond Charles   Smith Coleman   McKee Daniel   Boyd William   Kulig Clark   Bini Edmund   Pedrosa Marcos  

Digestive Diseases and Sciences, Vol. 56, Iss. 3, 2011-03 ,pp. : 880-888

Springer Publishing Company

Access to resources Recommend Favorite

Association of Interleukin-28B and Hepatitis C Genotype 1 with a High Viral Load and Response to Pegylated Interferon plus Ribavirin Therapy

By  

Digestion, Vol. 84, Iss. 1, 2011-12 ,pp. : 56-61

Karger

Access to resources Recommend Favorite

Successful Treatment With Novel Triple Drug Combination Consisting of Interferon-γ, Interferon Alfacon-1, and Ribavirin in a Nonresponder HCV Patient to Pegylated Interferon Therapy

By Balan Vijayan   Rosati Marianne   Anderson Machiko   Rakela Jorge  

Digestive Diseases and Sciences, Vol. 51, Iss. 5, 2006-05 ,pp. : 956-959

Springer Publishing Company

Access to resources Recommend Favorite

Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1

By  

Digestive Diseases, Vol. 33, Iss. 6, 2015-0 ,pp. : 708-714

Karger

Access to resources Recommend Favorite

Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C

By Tohra S.  

Digestive Diseases and Sciences, Vol. 56, Iss. 8, 2011-08 ,pp. : 2449-2455

Springer Publishing Company

Access to resources Recommend Favorite